Video

Dr. Graham on Utilizing Biomarkers to Guide Treatment in Intrahepatic Cholangiocarcinoma

Rondell Graham, MBBS, discusses utilizing biomarkers to guide treatment for patients with intrahepatic cholangiocarcinoma.

Rondell Graham, MBBS, an associate professor of Laboratory Medicine and Pathology at Mayo Clinic, discusses utilizing biomarkers to guide treatment for patients with intrahepatic cholangiocarcinoma.

Currently, tests are utilized to determine which patients may respond to treatment with novel inhibitors, according to Graham. For example, detecting FGFR2 fusions, which are present in approximately 20% of patients with intrahepatic cholangiocarcinoma, could indicate who might experience improved responses to those targeted therapies, Graham explains. Multiple studies have demonstrated the utility of testing for these biomarkers, and many drugs that target this mutation have gained regulatory approval, Graham notes. 

Additionally, IDH1 and IDH2 mutations are also detected in this patient population, Graham says. As such, patients with these mutations could be susceptible to treatment with IDH inhibitors, Graham adds. Data suggest that these therapies have led to disease stabilization, which is clinically meaningful because historically, poor rates of response to conventional chemotherapy have been observed in this patient population, Graham concludes.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity